DexCom

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. 

CEO
Jacob S. Leach
CEOJacob S. Leach
Employees
11,100
Employees11,100
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1999
Founded1999
Employees
11,100
Employees11,100

DXCM Key Statistics

Market cap
23.78B
Market cap23.78B
Price-Earnings ratio
30.93
Price-Earnings ratio30.93
Dividend yield
Dividend yield
Average volume
4.51M
Average volume4.51M
High today
$62.95
High today$62.95
Low today
$60.34
Low today$60.34
Open price
$62.68
Open price$62.68
Volume
3.59M
Volume3.59M
52 Week high
$89.98
52 Week high$89.98
52 Week low
$54.11
52 Week low$54.11

Stock Snapshot

As of today, DexCom(DXCM) shares are valued at $61.57. The company's market cap stands at 23.78B, with a P/E ratio of 30.93.

As of 2026-04-25, DexCom(DXCM) stock has fluctuated between $60.34 and $62.95. The current price stands at $61.57, placing the stock +2.0% above today's low and -2.2% off the high.

The DexCom(DXCM)'s current trading volume is 3.59M, compared to an average daily volume of 4.51M.

In the last year, DexCom(DXCM) shares hit a 52-week high of $89.98 and a 52-week low of $54.11.

In the last year, DexCom(DXCM) shares hit a 52-week high of $89.98 and a 52-week low of $54.11.

DXCM News

Nasdaq 2d
Intuit Moves Up In Analyst Rankings, Passing DexCom

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Intuit Inc (Symbol: INTU) has taken over the #30 sp...

Intuit Moves Up In Analyst Rankings, Passing DexCom
Nasdaq 2d
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins

Key Points Dexcom's devices could become even more popular thanks to weight loss drugs. The company has a vast addressable market. The medical device leader...

Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins
Simply Wall St 4d
DexCom’s Q1 2026 Earnings Might Change The Case For Investing In DexCom

DexCom, the San Diego-based continuous glucose monitoring company, released its fiscal first-quarter 2026 results on April 30, reporting diluted earnings of US$...

DexCom’s Q1 2026 Earnings Might Change The Case For Investing In DexCom

Analyst ratings

84%

of 31 ratings
Buy
83.9%
Hold
12.9%
Sell
3.2%

More DXCM News

Nasdaq 4d
Better Medical Device Stock Right Now: Abbott Laboratories vs. Dexcom

Key Points Abbott Laboratories and Dexcom are the biggest players in the market for continuous glucose monitoring devices. Abbott has a vast lineup of product...

Better Medical Device Stock Right Now: Abbott Laboratories vs. Dexcom

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.